Researchers from Ileadbms Co. Ltd. presented the discovery and preclinical characterization of IL-21120033, a new CXCR7 agonist being developed for the treatment of inflammatory bowel disease.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback